Related Experiment Videos
[The pathophysiology of adynamic bone disease].
K Yokoyama1, T Shigematsu, Y Ogura
1Division of Nephrology and Hypertension, Tokyo Jikei University School of Medicine.
Clinical Calcium
|March 19, 2005
Summary
Adynamic bone disease, common in dialysis patients, shows reduced bone turnover. Skeletal resistance to parathyroid hormone (PTH) is a key factor, potentially involving PTH receptor downregulation.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Context:
- Adynamic bone disease is a prevalent skeletal complication in patients undergoing dialysis.
- It is characterized by markedly reduced bone turnover.
- It is nearly as prevalent as osteitis fibrosis in hemodialysis patients.
Purpose:
- To summarize the current understanding of adynamic bone disease pathophysiology in dialysis patients.
- To highlight the role of skeletal resistance to parathyroid hormone (PTH).
Summary:
- Adynamic bone disease, noted since the 1980s, is the predominant bone lesion in peritoneal dialysis patients.
- Unlike osteomalacia, it features reduced bone turnover without increased osteoid formation.
- Skeletal resistance to PTH's calcemic action is a crucial factor, with recent studies suggesting PTH receptor downregulation and osteoclast inhibitory factor involvement.
Impact:
- Provides insight into the pathophysiology of a common complication in dialysis patients.
- Highlights potential therapeutic targets related to PTH signaling and bone metabolism.
- Contributes to understanding bone disease management in chronic kidney disease.